Artelo Biosciences

Artelo Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system.

Its pipeline includes ART27.13, a peripherally selective cannabinoid receptor agonist in Phase 2 for cancer-associated anorexia and cachexia, and ART26.12, a first-in-class FABP5 inhibitor in Phase 1 for chemotherapy-induced peripheral neuropathy.

The UK subsidiary at Alderley Park leads scientific direction, with MHRA engagement supporting pipeline development.